Preventive therapy for latent tuberculosis infection—the promise and the challenges
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Around one third of the world's population may harbour latent tuberculosis infection (LTBI), an asymptomatic immunological state that confers a heightened risk of subsequently developing tuberculosis (TB). Effectively treating LTBI will be essential if the End TB Strategy is to be realized. This review evaluates the evidence in relation to the effectiveness of preventive antibiotic therapy to treat LTBI due to both drug-susceptible and drug-resistant bacteria. Current national and international preventive therapy guidelines are summarized, as well as ongoing randomized trials evaluating regimens to prevent drug-resistant TB. Populations that may benefit most from screening and treatment for LTBI include close contacts of patients with TB (particularly children under 5 years of age) and individuals with substantial immunological impairment. The risks and benefits of treatment must be carefully balanced for each individual. Electronic decision support tools offer one way in which clinicians can help patients to make informed decisions. Modelling studies indicate that the expanded use of preventive therapy will be essential to achieving substantial reductions in the global TB burden. However, the widespread scale-up of screening and treatment will require careful consideration of cost-effectiveness, while ensuring the drivers of ongoing disease transmission are also addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jeon, C. Y., & Murray, M. B. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050152 · Cited by 1,486
Leung, C. C., Yu, I. T. S., & Chen, W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60235-9 · Cited by 1,193
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Horvath, T., Azman, H., Kennedy, G. E., & Rutherford, G. W. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009756 · Cited by 428 · cited 1×
“A range of available adherence support strategies include face-to-face direct observation of therapy (DOT – a recommended part of the 3HP regimen), regular patient review throughout treatment, mobile-phone based methods (including two-way SMS and staff phone contact) (81) and even video DOT.”
BackgroundA Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control
Churchyard, G. J., Fielding, K. L., Lewis, J. J., Coetzee, L., Corbett, E. L., Godfrey-Faussett, P., Hayes, R. J., Chaisson, R. E., & Grant, A. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1214289 · Cited by 238
Mycobacterial infections in solid organ transplant recipients
Meije, Y., Piersimoni, C., Torre-Cisneros, J., Dilektasli, A. G., & Aguado, J. M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12641 · Cited by 124
Cited by
Feng, J.-Y., Huang, W.-C., Lin, S.-M., Wang, T.-Y., Lee, S. S.-J., Shu, C.-C., Pan, S.-W., Chen, C.-Y., Lin, C.-B., Wei, Y.-F., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.05.009 · Cited by 24
Metadata
- Authors
- Fox, G. J., Dobler, C. C., Marais, B. J., & Denholm, J. T.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 56
- Pages
- 68-76
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W2556933102
- Cited by
- 162
- References
- 6
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preventive therapy for latent tuberculosis infection—the promise and the challenges. https://app.cochat.ai/papers/10.1016/j.ijid.2016.11.006
- The paper
- Fox, G. J., Dobler, C. C., Marais, B. J., & Denholm, J. T. (2017). Preventive therapy for latent tuberculosis infection—the promise and the challenges. International Journal of Infectious Diseases. https://doi.org/10.1016/j.ijid.2016.11.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.